HGS Regains Full Rights To TRAIL Antibodies From GSK
This article was originally published in The Pink Sheet Daily
Executive Summary
Maryland biotech swaps oncology candidates for reduced royalties on type 2 diabetes candidate.
You may also be interested in...
Human Genome Sciences Reports First Phase II Findings For TRAIL Receptor Agonist Mapatumumab
Phase II results termed “unimpressive,” though firm says potential partners show interest.
Human Genome Sciences Reports First Phase II Findings For TRAIL Receptor Agonist Mapatumumab
Phase II results termed “unimpressive,” though firm says potential partners show interest.
HGS Invests In Oncology As Phase III Drugs Near Submission
Human Genome Sciences targets 2010 for Albuferon and LymphoStat-B launches.